Paraneoplastic pemphigus: A trait d’union between dermatology and oncology

Dario Didona, Biagio Didona, Antonio G Richetta, Carmen Cantisani, Elisa Moliterni, Stefano Calvieri, Giovanni Paolino

Abstract


Paraneoplastic pemphigus is a rare autoimmune disease of the skin associated with neoplasm. Nowadays, the pathogenesis of paraneoplastic pemphigus is not fully understood. Due to its rarity, various criteria have been proposed for the diagnosis. For this reason, several diagnostic methods have been considered useful for the diagnosis of paraneoplastic pemphigus including indirect immunofluorescence, direct immune of fluorescence, immunoprecipitation, immunoblotting, and enzyme-linked immunosorbent assay (ELISA). However, the polymorphic clinical features and the various results of laboratory tests and pathological evaluation present a challenge for the clinicians.

Keywords


paraneoplastic pemphigus; oncology; cancer; therapy

Full Text:

PDF

References


Anhalt GJ, Kim SC, Stanley JR, et al. Paraneoplastic pemphigus. An autoimmune mucocutaneous disease associated with neoplasia. N Engl J Med 1990; 323(25): 1729–1735. doi: 10.1056/NEJM199012203232503

Sehgal VN, Srivastava G. Paraneoplastic pemphigus/paraneoplastic autoimmune multiorgan syndrome. Int J Dermatol 2009; 48(2): 162–169. doi: 10.1111/j.1365-4632.2009.03995.x

Nguyen VT, Ndoye A, Bassler KD, et al. Classification, clinical manifestations, and immunopathological mechanisms of the epithelial variant of paraneoplastic auto-immune multiorgan syndrome: a reappraisal of paraneoplastic pemphigus. Arch Dermatol 2001; 137(2): 193–206.

Anhalt GJ. Paraneoplastic pemphigus. J Invest Dermatol Symp Proc 2004; 9(1): 29–33. doi: 10.1111/j.1087-0024.2004.00832.x

Vassileva S, Drenovska K, Manuelyan K. Autoimmune blistering dermatoses as systemic diseases. Clin Dermatol 2014; 32(3): 364–375. doi: 10.1016/j.clindermatol.2013.11.003

Czernik A, Camilleri M, Pittelkow MR, et al. Paraneoplastic autoimmune multiorgan syndrome: 20 years after. Int J Dermatol 2011; 50(8): 905–914. doi: 10.1111/j.1365-4632.2011.04868.x

Ogawa H, Sakuma M, Morioka S, et al. The incidence of external malignancies in pemphigus and bullous pemphigoid in Japan. J Dermatol Sci 1995; 9(2): 135–141. doi: 10.1016/0923-1811(94)00371-K

Cervini AB, Tosi V, Kim SH, et al. Paraneoplastic pemphigus or paraneoplastic autoimmune multiorgan syndrome. Report of 2 cases in children and a review of the literature. Actas Dermosifiliogr 2010; 101(10): 879–886. doi: 10.1016/j.ad.2010.06.012

Mimouni D, Anhalt GJ, Lazarova Z, et al. Paraneoplastic pemphigus in children and adolescents. Br J Dermatol 2002; 147(4): 725–732. doi: 10.1046/j.1365-2133.2002.04992.x

Lane JE, Woody C, Davis LS, et al. Paraneoplastic autoimmune multiorgan syndrome (paraneoplastic pemphigus) in a child: case report and review of the literature. Pediatrics 2004; 114(4): 513–516. doi: 10.1542/peds.2004-0436

Yong AA, Tey HL. Paraneoplastic pemphigus. Australas J Dermatol 2013; 54(4): 241–250. doi: 10.1111/j.1440-0960.2012.00921.x

Bowen GM, Peters NT, Fivenson DP, et al. Lichenoid dermatitis in paraneoplastic pemphigus: a pathogenic trigger of epitope spreading? Arch Dermatol 2000; 136(5): 652–656. doi: 10.1001/archderm.136.5.652

Matz H, Milner Y, Frusic-Zlotkin M, et al. Paraneoplastic pemphigus associated with pancreatic carcinoma. Acta Derm Venereol 1997; 77(4): 289–291.

Wong KC, Ho KK. Pemphigus with pemphigoid-like presentation, associated with squamous cell carcinoma of the tongue. Australas J Dermatol 2000; 41(3): 178–180. doi: 10.1046/j.1440-0960.2000.00434.x

Lee IJ, Kim SC, Kim HS, et al. Paraneoplastic pemphigus associated with follicular dendritic cell sarcoma arising from Castleman’s tumor. J Am Acad Dermatol 1999; 40(2 Pt 2): 294–297. doi: 10.1016/S0190-9622(99)70468-8

VanderWaal RI, Pas HH, Anhalt GJ, et al. PNP as the presenting symptom of lymphoma of the tongue. Oral Oncol 1998; 34(6): 567–570. doi: 10.1016/S1368-8375(98)00020-7

Schaeppi H, Bauer JW, Hametner R, et al. Localized variant of paraneoplastic pemphigus: acantholysis associated with malignant melanoma. Br J Dermatol 2001; 144(6): 1249–1254. doi: 10.1046/j.1365-2133.2001.04243.x

Bazarbachi A, Bachelez H, Dehen L, et al. Lethal paraneoplastic pemphigus following treatment of chronic lymphocytic leukaemia with fludarabine. Ann Oncol 1995; 6(7): 730–731.

Anhalt GJ. Paraneoplastic pemphigus: the role of tumours and drugs. Br J Dermatol 2001; 144(6): 1102–1104. doi: 10.1046/j.1365-2133.2001.04272.x

Lee MS, Kossard S, Ho KK, et al. Paraneoplastic pemphigus triggered by radiotherapy. Australas J Dermatol 1995; 36(4): 206–210. doi: 10.1111/j.1440-0960.1995.tb00976.x

Martel P, Loiseau P, Joly P, et al. Paraneoplastic pemphigus is associated with the DRB1*03 allele. J Autoimmun 2003; 20(1): 91–95. doi: 10.1016/S0896-8411(02)00092-6

Liu Q, Bu DF, Li D, et al. Genotyping of HLA-I and HLA-II alleles in Chinese patients with paraneoplastic pemphigus. Br J Dermatol 2008; 158(3): 587–591. doi: 10.1111/j.1365-2133.2007.08361.x

Kiyokawa C, Ruhrberg C, Nie Z, et al. Envoplakin and periplakin are components of the paraneoplastic pemphigus antigen complex. J Invest Dermatol 1998; 111(6): 1236–1238. doi: 10.1046/j.1523-1747.1998.00449.x

Kim SC, Kwon YD, Lee IJ, et al. cDNA cloning of the 210-kDa paraneoplastic pemphigus antigen reveals that envoplakin is a component of the antigen complex. J Invest Dermatol 1997; 109(3): 365–369. doi: 10.1111/1523-1747.ep12336235

Oursler JR, Labib RS, Ariss-Abdo L, et al. Human auto-antibodies against desmoplakins in paraneoplastic pemphigus. J Clin Invest 1992; 89(6): 1775–1782. doi: 10.1172/JCI115781

Borradori L, Trueb RM, Jaunin F, et al. Autoantibodies from a patient with paraneoplastic pemphigus bind periplakin, a novel member of the plakin family. J Invest Dermatol 1998; 111(2): 338–340. doi: 10.1046/j.1523-1747.1998.00280.x

Lambert J, Bracke S, van Roy F, et al. Serum plakophilin-3 autoreactivity in paraneoplastic pemphigus. Br J Dermatol 2010; 163(3): 630–632. doi: 10.1111/j.1365-2133.2010.09845.x

Brandt O, Rafei D, Podstawa E, et al. Differential IgG recognition of desmoglein 3 by paraneoplastic pemphigus and pemphigus vulgaris sera. J Invest Dermatol 2012; 132(6): 1738–1741. doi: 10.1038/jid.2012.1

Amagai M, Nishikawa T, Nousari HC, et al. Antibodies against desmoglein 3 (pemphigus vulgaris antigen) are present in sera from patients with paraneoplastic pemphigus and cause acantholysis in vivo in neonatal mice. J Clin Invest 1998; 102(4): 775–782. doi: 10.1172/JCI3647

Zimmermann J, Bahmer F, Rose C, et al. Clinical and immunopathological spectrum of paraneoplastic pemphigus. J Dtsch Dermatol Ges 2010; 8(8): 598–606. doi: 10.1111/j.1610-0387.2010.07380.x

Numata S, Teye K, Tsuruta D, et al. Anti-alpha-2-macroglobulin-like-1 autoantibodies are detected frequently and may be pathogenic in paraneoplastic pemphigus. J Invest Dermatol 2013; 133(7): 1785–1793. doi: 10.1038/jid.2013.65

Schepens I, Jaunin F, Begre N, et al. The protease inhibitor alpha-2-macroglobulin-like-1 is the p170 antigen recognized by paraneoplastic pemphigus autoantibodies in human. PLoS One 2010; 5(8): e12250. doi: 10.1371/journal.pone.0012250

Billet SE, Grando SA, Pittelkow MR. Paraneoplastic autoimmune multiorgan syndrome: review of the literature and support for a cytotoxic role in pathogenesis. Autoimmunity 2006; 39(7): 617–630. doi: 10.1080/08916930600972099

Reich K, Brinck U, Letschert M, et al. Graft-versus-host disease-like immunophenotype and apoptotic keratinocyte death in paraneoplastic pemphigus. Br J Dermatol 1999; 141(4): 739–746. doi: 10.1046/j.1365-2133.1999.03123.x

Cummins DL, Mimouni D, Tzu J, et al. Lichenoid paraneoplastic pemphigus in the absence of detectable antibodies. J Am Acad Dermatol 2007; 56(1): 153–159. doi: 10.1016/j.jaad.2006.06.007

Wade MS, Black MM. Paraneoplastic pemphigus: a brief update. Australas J Dermatol 2005; 46: 1–8. doi: 10.1111/j.1440-0960.2005.126_1.x

Bialy-Golan A, Brenner S, Anhalt GJ. Paraneoplastic pemphigus: oral involvement as the sole manifestation. Acta Derm Venereol 1996; 76(3): 253–254.

Lee SE, Kim SC. Paraneoplastic pemphigus. Dermatol Sin 2010; 28(1): 1–14. doi: 10.1016/S1027-8117(10)60001-8

Vassileva S, Drenovska K, Manuelyan K. Auto-immune blistering dermatoses as systemic diseases. Clin Dermatol 2014; 32(3): 364–375. doi: 10.1016/j.clindermatol.2013.11.003

Zhu X, Zhang B. Paraneoplastic pemphigus. J Dermatol 2007; 34(8): 503–511. doi: 10.1111/j.1346-8138.2007.00322.x

Lee SE, Hashimoto T, Kim SC. No mucosal involvement in a patient with paraneoplastic pemphigus associated with thymoma and myasthenia gravis. Br J Dermatol 2008; 159(4): 986–988. doi: 10.1111/j.1365-2133.2008.08763.x

Meyers SJ, Varley GA, Meisler DM, et al. Conjunctival involvement in paraneoplastic pemphigus. Am J Ophthalmol 1992; 114(5): 621–624. doi: 10.1016/S0002-9394(14)74494-0

Ng PP, Rencic A, Nousari HC. Paraneoplastic pemphigus: a refractory autoimmune mucocutaneous disease. J Cutan Med Surg 2002; 6(5): 434–437. doi: 10.1007/s10227-001-0130-x

Mutasim DF, Pelc NJ, Anhalt GJ. Paraneoplastic pemphigus. DermatolClin 1993; 11(3): 473–481.

Tankel M, Tannenbaum S, Parekh S. Paraneoplastic pemphigus presenting as an unusual bullous eruption. J Am Acad Dermatol 1993; 29(5 Pt 2): 825–858.

Sapadin AN, Anhalt GJ. Paraneoplastic pemphigus with a pemphigus vegetans-like plaque as the only cutaneous manifestation. J Am Acad Dermatol 1998; 39(5 Pt 2): 867–871. doi: 10.1016/S0190-9622(98)70368-8

Maldonado F, Pittelkow MR, Ryu JH. Constrictive bronchiolitis associated with paraneoplastic autoimmune multi-organ syndrome. Respirology 2009; 14(1): 129–133. doi: 10.1111/j.1440-1843.2008.01397.x

Joly P, Richard C, Gilbert D, et al. Sensitivity and specificity of clinical, histologic, and immunologic features in the diagnosis of paraneoplastic pemphigus. J Am Acad Dermatol 2000; 43(4): 619–626. doi: 10.1067/mjd.2000.107488

Helou J, Allbritton J, Anhalt G. Accuracy of indirect immunofluorescence in the diagnosis of paraneoplastic pemphigus. J Am Acad Dermatol 1995; 32(3): 441–447. doi: 10.1016/0190-9622(95)90066-7

Cozzani E, Dal Bello MG, Mastrogiacomo A, et al. Antidesmoplakin antibodies in pemphigus vulgaris. Br J Dermatol 2006; 154(4): 624–628. doi: 10.1111/j.1365-2133.2005.06987.x

Kazerounian S, Mahoney MG, Uitto J, et al. Envoplakin and periplakin, the paraneoplastic pemphigus antigens, are also recognized by pemphigus foliaceus auto-antibodies. J Invest Dermatol 2000; 115(3): 505–507. doi: 10.1046/j.1523-1747.2000.00088-2.x

Ishii N, Maeyama Y, Karashima T, et al. Immunoserological analyses of 55 patients with pemphigus at the Dermatological Department of Kurume University Hospital: an 11-year retrospective study (1996–2006). Int J Dermatol 2008; 47(12): 1321–1322. doi: 10.1111/j.1365-4632.2008.03712.x

Probst C, Schlumberger W, Stöcker W, et al. Development of ELISA for the specific determination of autoantibodies against envoplakin and periplakin in paraneoplastic pemphigus. Clin Chim Acta 2009; 410(1-2): 13–18. doi: 10.1016/j.cca.2009.08.022

Ishii N, Teye K, Fukuda S et al. Anti-desmocollin autoantibodies in nonclassical pemphigus. Br J Dermatol 2015 Jul; 3(1): 59–68. doi: 10.1111/bjd.13711

Hashimoto T, Amagai M, Watanabe K, et al. Characterization of paraneoplastic pemphigus autoantigens by immunoblot analysis. J Invest Dermatol 1995; 104(5): 829–834. doi: 10.1111/1523-1747.ep12607012

Camisa C, Helm TN. Paraneoplastic pemphigus is a distinct neoplasia-induced autoimmune disease. Arch Dermatol 1993; 129(7): 883–886. doi: 10.1001/archderm.1993.01680280071014

Ohzono A, Sogame R, Li X, et al. Clinical and immuno-logical findings in 104 cases of paraneoplastic pemphigus. Br J Dermatol 2015 Sep 10. doi: 10.1111/bjd.14162. [Epub ahead of print]

Hata T, Nishimoto S, Nagao K, et al. Ectopic expression of epidermal antigens renders the lung a target organ in paraneoplastic pemphigus. J Immunol 2013; 191(1): 83–90. doi: 10.4049/jimmunol.1203536

Poot AM, Diercks GF, Kramer D, et al. Laboratory diagnosis of paraneoplastic pemphigus. Br J Dermatol 2013; 169(5): 1016–1024. doi: 10.1111/bjd.12479

Dega H, Laporte JL, Joly P, et al. Paraneoplastic pemphigus associated with Hodgkin’s disease. Br J Dermatol 1998; 138(1): 196–198. doi: 10.1046/j.1365-2133.1998.02056.x

Martínez De Pablo MI, Iranzo P, et al. Paraneoplastic pemphigus associated with non-Hodgkin B-cell lymphoma and good response to prednisone. Acta Derm Venereol 2005; 85(3): 233–235.

Gergely L, Váróczy L, Vadász G, et al. Successful treatment of B cell chronic lymphocytic leukemia-associated severe paraneoplastic pemphigus with cyclosporin A. Acta Haematol 2003; 109(4): 202–205. doi: 10.1159/000070972

Williams JV, Marks JG, Billingsley EM. Use of myco-phenolate mofetil in the treatment of paraneoplastic pemphigus. Br J Dermatol 2000; 142(3): 506–508. doi: 10.1046/j.1365-2133.2000.03365.x

Hertzberg MS, Schifter M, Sullivan J, et al. Paraneoplastic pemphigus in two patients with B-cell non-Hodgkin’s lymphoma: significant responses to cyclophosphamide and prednisolone. Am J Hematol 2000; 63(2): 105–106. doi: 10.1002/(sici)1096-8652(200002)63:23.0.co;2-c

Hayag MV, Cohen JA, Kerdel FA. Immunoablative high-dose cyclophosphamide without stem cell rescue in a patient with pemphigus vulgaris. J Am Acad Dermatol 2000; 43(6): 1065–1069. doi: 10.1067/mjd.2000.110397

Tan-Lim R, Bystryn JC. Effect of plasmapheresis therapy on circulating levels of pemphigus antibodies. J Am Acad Dermatol 1990; 22(1): 35–40. doi: 10.1016/0190-9622(90)70004-2

Izaki S, Yoshizawa Y, Kitamura K, et al. Paraneoplastic pemphigus: potential therapeutic effect of plasmapheresis. Br J Dermatol 1996; 134(5): 987–989. doi: 10.1111/j.1365-2133.1996.tb06349.x

Hertl M, Zillikens D, Borradori L, et al. Recommendations for the use of rituximab (anti-CD20 antibody) in the treatment of autoimmune bullous skin diseases. J Dtsch Dermatol Ges 2008; 6(5): 366–373. doi: 10.1111/j.1610-0387.2007.06602.x

Hainsworth JD, Burris HA, Morrissey LH, et al. Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin’s lymphoma. Blood 2000; 95(10): 3052–3056.

Hohwy T, Bang K, Steiniche T, et al. Alemtuzumab-induced remission of both severe paraneoplastic pemphigus and leukaemic bone marrow infiltration in a case of treatment-resistant B-cell chronic lymphocytic leukaemia. Eur J Haematol 2004; 73(3): 206–209. doi: 10.1111/j.1600-0609.2004.00280.x

Wang J, Zhu X, Li R, et al. Paraneoplastic pemphigus associated with Castleman tumor: a commonly reported subtype of paraneoplastic pemphigus in China. Arch Dermatol 2005; 141(10): 1285–1293. doi: 10.1001/archderm.141.10.1285

Dong Y, Wang M, Nong L, et al. Clinical and laboratory characterization of 114 cases of Castleman disease patients from a single centre: paraneoplastic pemphigus is an unfavourable prognostic factor. Br J Haematol 2015; 169(6): 834–842. doi: 10.1111/bjh.13378




DOI: http://dx.doi.org/10.30564/amor.v1i2.17

Refbacks

  • There are currently no refbacks.


Copyright (c) 2018 Dario Didona, Biagio Didona, Antonio G Richetta, Carmen Cantisani, Elisa Moliterni, Stefano Calvieri, Giovanni Paolino

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.